NCT04163094View on ClinicalTrials.gov

Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

June 26, 2023

Study Completion Date

June 26, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

W_ova1 Vaccine

Patients will be treated with a W\_ova1 vaccine that includes 3 OC TAA RNA-LPX products.

Trial Locations (1)

9713GZ

UMCG, Groningen

Sponsors

Collaborators (1)

BioNTech SE
All Listed Sponsors
collaborator

BioNTech SE

INDUSTRY

lead

University Medical Center Groningen

OTHER